Possible role of imatinib in clinical pulmonary veno-occlusive disease

European Respiratory Journal

Volumn 32, Issue 1, 2008, Pages 232-235

  Overbeek, M J ^a   Van Nieuw Amerongen, G P ^a   Boonstra, A ^a   Smit, E F ^a   Vonk Noordegraaf, A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Imatinib; Platelet derived growth factor receptor; Pulmonary arterial hypertension; Pulmonary veno occlusive disease; Vascular permeability

Indexed keywords

ANTICOAGULANT AGENT; BOSENTAN; FUROSEMIDE; IMATINIB; PROSTACYCLIN; SILDENAFIL; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; VASODILATOR AGENT;

ADULT; ALOPECIA; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG POTENTIATION; ECHOCARDIOGRAPHY; FEMALE; GENETIC SCREENING; HEART CATHETERIZATION; HEART OUTPUT; HEART RIGHT ATRIUM PRESSURE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LABORATORY TEST; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; LUNG VASCULAR RESISTANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; TREATMENT OUTCOME; DRUG COMBINATION; MIDDLE AGED;

DRUG THERAPY, COMBINATION; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PULMONARY VENO-OCCLUSIVE DISEASE; PYRIMIDINES; VASODILATOR AGENTS;

EID: 52749098471     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00054407     Document Type: Article

References (19)

1. Davies P, Reid L. Pulmonary veno-occlusive disease in siblings: case reports and morphometric study. Hum Pathol 1982; 13: 911-915.
2. Voordes CG, Kuipers JR, Elema JD. Familial pulmonary veno-occlusive disease: a case report. Thorax 1977; 32: 763-766.
3. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353: 1412-1413.
4. Assaad AM, Kawut SM, Arcasoy SM, et al. Platelet-derived growth factor is increased in pulmonary capillary hemangiomatosis. Chest 2007; 131: 850-855.
5. Heath D, Segel N, Bishop J. Pulmonary veno-occlusive disease. Circulation 1966; 34: 242-248.
6. Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162: 1964-1973.
7. Wagenvoort CA, Wagenvoort N, Takahashi T. Pulmonary veno-occlusive disease: involvement of pulmonary arteries and review of the literature. Hum Pathol 1985; 16: 1033-1041.
8. Lantuejoul S, Sheppard MN, Corrin B, Burke MM, Nicholson AG. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol 2006; 30: 850-857.
9. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61: 68-74.
10. Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006; 145: 152-153.
11. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006; 61: 736.
12. Gan CT, McCann GP, Marcus JT, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. Eur Respir J 2006; 28: 1190-1194.
13. Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 2006; 98: 525-529.
14. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129: 1313-1321.
15. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821.
16. Harhaj NS, Barber AJ, Antonetti DA. Platelet-derived growth factor mediates tight junction redistribution and increases permeability in MDCK cells. J Cell Physiol 2002; 193: 349-364.
17. Kurimoto N, Nan YS, Chen ZY, et al. Effects of specific signal transduction inhibitors on increased permeability across rat endothelial monolayers induced by neuropeptide Y or VEGF. Am J Physiol Heart Circ Physiol 2004; 287: H100-H106.
18. Jayson GC, Parker GJ, Mullamitha S, et al. Blockade of platelet-derived growth factor receptor-β by CDP860, a humanized, PEGylated di-Fab′, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 2005; 23: 973-981.
19. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61: 2929-2934.